Gene-Guided blood thinners aim to cut bleeding risks
NCT ID NCT07602257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using a patient's genetic information to choose anti-platelet drugs can lower bleeding risks compared to standard care. About 1,760 high-risk patients receiving a heart stent will be assigned to either a personalized drug plan or usual therapy. The goal is to see if tailoring treatment reduces serious bleeding events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ticagrelor, Aspirin, Clopidogrel (Plavix)
What this could lead to
If successful, this could lead to a safer, personalized way to prescribe anti-platelet drugs, reducing bleeding complications in heart patients.
What could go wrong
This is a pilot study, so results are preliminary. The approach may not reduce bleeding as hoped, and genetic testing adds complexity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••